Method Development

QPS works with you to develop assays using the most appropriate technology platform. Before any method development work is undertaken, we sit down and discuss with you the assay requirement and its intended use, such as:

  • Tier 1 Discovery vs. Tier 2 Discovery vs. candidate selection criteria vs. regulated bioanalysis

  • Possible metabolites for small molecules

  • LC-MS/MS or LBA for oligonucleotide-based drugs, any modifications and the required specificity and sensitivity

  • LC-MS/MS or LBA for peptide and polypeptide drugs

  • Monoclonal or polyclonal antibodies for biologics

 

Our staff has considerable experience with the conventional matrices (plasma, serum, whole-blood, urine, feces), as well as various animal and human tissues, including:

  • Liver

  • Bile

  • Brain

  • Cerebrospinal fluid (CSF)

  • Myocardium

  • Coronary arterial tissue

  • Arterial tissue

  • Skin

  • Spleen

  • Prostate

  • Small intestine

  • Kidney

  • Lung

  • Bronchial alveolar fluid (BAL)

  • Retina

  • Vitreous humor

  • Aqueous humor

  • Tumor tissue

  • Plasma/culture media

  • Plasma extracts

  • Human serum albumin (HSA)

  • Alpha-acid glycoprotein (AAG)

  • Red blood cells

  • Peripheral blood mononuclear cell (PBMC)

  • Microsomes

  • S9

  • Hepatocytes

  • cDNA